Randomized, Double-Masked, Active Controlled, Crossover Phase IIIEquivalence Study of Travoprost Eye Drops Solution in Subjects withOpen Angle Glaucoma or Ocular Hypertension - Travoprost equivalence study

Start Date05 May 2011

Sponsor / Collaborator

Alfred E. Tiefenbacher (GmbH & Co. KG)

NCT00878917

/ CompletedPhase 3

Randomized, Double-Masked, Active Controlled, Crossover Phase III Equivalence Study of Dorzolamide 2% Eye Drops Solution In Subjects With Open Angle Glaucoma Or Ocular Hypertension

The study aims to prospectively prove the equivalence of the test product and the reference solution in lowering intraocular pressure in patients with open angle glaucoma and ocular hypertension. For this purpose the patients are randomized into two sequences of study drug administration in a crossover study with an adequate wash-out period.

Start Date01 Apr 2009

Sponsor / Collaborator

Alfred E. Tiefenbacher (GmbH & Co. KG)

EUCTR2009-009182-34-DE

/ Not yet recruitingPhase 3

RANDOMIZED, DOUBLE MASKED; ACTIVE CONTROLLED, CROSSOVER PHASE III EQUIVALENCE STUDY OF DORZOLAMIDE 2 % EYE DROPS SOLUTION IN SUBJECTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION - Dorzolamide 2008 Study

Start Date30 Mar 2009

Sponsor / Collaborator

Alfred E. Tiefenbacher (GmbH & Co. KG)

100 Clinical Results associated with Alfred E. Tiefenbacher (GmbH & Co. KG)

0 Patents (Medical) associated with Alfred E. Tiefenbacher (GmbH & Co. KG)

Literatures (Medical) associated with Alfred E. Tiefenbacher (GmbH & Co. KG)

20 Jul 2022·Journal of Ophthalmology

A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Article

Author: Pfeiffer, Norbert ; Strzalkowska, Alicja ; Lorenz, Katrin ; Bell, Katharina ; Ruckes, Christian ; Klingberg, Ulrike ; Butsch, Christina ; Korb, Christina ; Beck, Anna ; Giers, Bert Constantin

Background. The aim of this study was to demonstrate the equivalence of generic dorzolamide 2% eye drops solution versus the innovator formulation (Trusopt® eye drops solution) in patients with open-angle glaucoma or ocular hypertension. Methods. This prospective, monocentric, double-masked, active-controlled crossover phase III study included 32 patients. After washout, patients were randomized to reference product (Trusopt®) or test product (dorzolamide 2% eye drops, Rompharm Company SRL) for a 4-week period. Subsequent washout and crossover were performed. Drops were applied t.i.d. The primary efficacy endpoint was the difference in mean diurnal IOP. Goldmann applanation tonometry was performed at 8 am, 12 pm, and 4 pm at each visit, and safety was assessed by documentation of adverse events (AEs). Therapy adherence was documented by self-reporting and eye drop bottle weighing. An ANOVA with treatment, sequence, study period, and patient within the sequence as effects was performed and an additional post hoc ANCOVA including the baseline IOP was also performed. Results. 34 patients were randomized and analyzed in the safety population. The per-protocol population included 32 patients. According to the self-report, all patients were >80% compliant. Under the ANCOVA model, the 90% confidence interval for the average change of the IOP −0.27 mmHg (−1.17 mmHg–0.64 mmHg) is included by the acceptance range −1.5 mmHg to +1.5 mmHg after excluding 2 patients, which had falsely reported high therapy adherence. No clinically relevant difference was observed in frequency or severity of the AEs between both treatments. Conclusions. This study showed the equivalence of the tested generic dorzolamide 2% eye drops solution to the reference product Trusopt® eye drops solution. Trial Registration. This trial is registered with (ClinicalTrials.gov (identifier: NCT00878917) on April 9, 2009).

01 Jun 2022·Diabetes Therapy

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers

Article

Author: Klingberg, Ulrike ; Schnaars, Yvonne ; Prathap, Vamshi Ramana ; Vadla, Hari Kiran Chary ; Gottwald-Hostalek, Ulrike ; Gaikwad, Sumedh

INTRODUCTIONVildagliptin and metformin are two well-established oral antidiabetics with a complementary mechanism of action. Two new generic products, vildagliptin and its fixed-drug combination (FDC) with metformin, were tested for bioequivalence versus the approved originator reference products (Galvus® and Eucreas®).METHODSThree randomized studies with two-treatment, two-period, two-sequence crossover design were conducted in healthy adults. One study evaluated vildagliptin 50 mg tablets as single dose under fasting conditions. Vildagliptin-metformin FDC tablet strengths of 50/850 mg and 50/1000 mg were evaluated in separate studies as single dose under fed conditions, given 30 min after a standardized high-fat, high-calorie breakfast following 10 h overnight fasting. Blood samples for analysis were collected until 24 h after dosing in each study period. Bioequivalence between test (T) and reference (R) products required 90% confidence interval (CIs) for the geometric least square (LS) mean T/R ratio to be within 80-125% for the pharmacokinetic parameters, maximum plasma concentration (C_max), and area under the curve (AUC_0-t).RESULTSThe 90% CIs of geometric LS means of T/R ratio for C_max and AUC_0-t with vildagliptin tablets of 50 mg were 92.22-103.94% and 99.00-102.66%, respectively; corresponding results with FDC tablets for 50/850 mg tablets were 94.81-115.41% and 95.28-106.00% for vildagliptin and 90.87-101.18% and 90.56-100.09% for metformin; for 50/1000 mg tablets C_max and AUC_0-t were 105.56-122.30% and 98.30-107.55%, respectively, for vildagliptin and 92.14-103.73% and 94.60-101.81%, respectively, for metformin. Other parameters such as AUC_0-∞, time to maximum concentration (T_max), and terminal half-life (t_1/2) were comparable between test and reference products. Adverse events (AEs), mainly vomiting, were reported without relevant difference between test and reference products in each study. AEs were generally mild and transient. No severe or serious AEs occurred.CONCLUSIONSThe new generic drug products of vildagliptin and the FDCs of vildagliptin and metformin demonstrated bioequivalence to the approved originator products and are therefore expected to provide similar therapeutic effects.

Journal of Global Trends in Pharmaceutical Sciences

Bioequivalence, safety and tolerability of Dasatinib tablets 140 mg in healthy adult volunteers under fasting conditions

Author: Pradeep, T. Pavan ; Rao, A. V. Krishna ; Ulrike, Klingberg ; Kumar, N. Ravi

The objective of this study was to determine the comparative pharmacoki-netics, safety and tolerability of test formulation Dasatinib tablets 140 mg with reference formulation Sprycel 140 mg filmtabletten after single dose administration under fasting conditions in 24 healthy adult male and female volunteers.This was an open label, two periods, two treatments, two-way crossover, controlled, block randomized, bioequivalence study in male and female, healthy volunteers, under fasting conditions.Each subject received a Dasatinib tablets 140 mg of test and reference product in each period re-spectively.Blood samples were collected before dosing and at various time points up to 24 h after drug administration.A total of 20 subjects re-ceived one dose of Dasatinib tablets 140 mg (TEST) or one dose of SPRYCEL 140 mg Filmtabletten (Reference) in two different occa-sions separated by a wash-out period of 16 days.Twenty eight (28) adverse events of mild and moderate intensity occurred in fourteen subjects in the study.These were not serious adverse events and the volunteers completely recovered before the end of the study.The statistical anal. of the phar-macokinetic data obtained in this study shows that the two Dasatinib formu-lations, Dasatinib tablets 140 mg of MSN Laboratories Pvt.Ltd., India - TEST and SPRYCEL 140 mg Filmtabletten, formulation of BRISTOL-MYERS SQUIBB PHARMA EEIG, United Kingdom - Reference are not bioequivalent, in fasting conditions.The Dasatinib Tablets 140 mg treatments (TEST and Reference), administered in single dose, orally, to male and female healthy volunteers, in fasting conditions were well tol-erated by all the subjects in this study.

100 Deals associated with Alfred E. Tiefenbacher (GmbH & Co. KG)

100 Translational Medicine associated with Alfred E. Tiefenbacher (GmbH & Co. KG)

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Losartan Potassium ( AT1R )	Hypertension More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis